Vonoprazan and amoxicillin dual therapy as the first‐line treatment of Helicobacter pylori infection: A systematic review and meta‐analysis

医学 阿莫西林 内科学 幽门螺杆菌 不利影响 科克伦图书馆 荟萃分析 胃肠病学 随机对照试验 抗生素 微生物学 生物
作者
Ren‐Chun Du,Yuxin Hu,Yaobin Ouyang,Li‐Xiang Ling,Jing‐Yuan Xu,Rina Sa,Xiao‐Shun Liu,Junbo Hong,Yin Zhu,Nonghua Lü,Yi Hu
出处
期刊:Helicobacter [Wiley]
卷期号:29 (1) 被引量:23
标识
DOI:10.1111/hel.13039
摘要

Abstract Background Recent clinical trials have evaluated the efficacy of vonoprazan‐amoxicillin (VA) dual therapy as the first‐line treatment for Helicobacter pylori infection in different regions with inconsistent results reported. In this systematic review and meta‐analysis, we aimed to evaluate the efficacy of VA dual therapy compared to the currently recommended therapy for eradicating H. pylori . Materials and Methods A comprehensive search of the PubMed, Cochrane, and Embase databases was performed using the following search terms: (“ Helicobacter ” OR “ H. pylori ” OR “ Hp ”) AND (“vonoprazan” OR “potassium‐competitive acid blocker” OR “P‐CAB”) AND (“amoxicillin” OR “penicillin”) AND (“dual”). The primary outcome was to evaluate the eradication rate according to intention‐to‐treat and per‐protocol analysis. The secondary outcomes were adverse events and compliance. Results A total of 15 studies involving 4, 568 patients were included. The pooled eradication rate of VA dual therapy was 85.0% and 90.0% by intention‐to‐treat and per‐protocol analysis, respectively. The adverse events rate and compliance of VA dual therapy were 17.5% and 96%, respectively. The efficacy of VA dual therapy was superior to proton pump inhibitors‐based triple therapy (82.0% vs. 71.4%, p < 0.01) but lower than vonoprazan‐containing quadruple therapy (83.1% vs. 93.3%, p = 0.02). 7‐day VA dual therapy showed lower eradication rates than 10‐day (χ 2 = 24.09, p < 0.01) and 14‐day VA dual therapy (χ 2 = 11.87, p < 0.01). The adverse events rate of VA dual therapy was lower than vonoprazan triple therapy (24.6% vs. 30.9%, p = 0.01) and bismuth‐containing quadruple therapy (20.5% vs. 47.9%, p < 0.01). No significant difference of compliance was observed between VA dual therapy and each subgroup. Conclusion VA dual therapy, a novel regimen, showed high efficacy as the first‐line treatment for H. pylori eradication, which should be optimized before application in different regions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
梓默完成签到 ,获得积分10
刚刚
我是老大应助Japan采纳,获得10
1秒前
彬琪完成签到,获得积分10
1秒前
红尘踏歌完成签到,获得积分10
1秒前
不忘初心发布了新的文献求助10
2秒前
18746005898完成签到 ,获得积分10
2秒前
chenkaixin完成签到,获得积分10
3秒前
WangZhen完成签到,获得积分20
4秒前
乔木木完成签到,获得积分10
4秒前
一路畅通accept完成签到,获得积分10
4秒前
潇湘学术完成签到,获得积分10
4秒前
烂漫的如冬完成签到,获得积分10
5秒前
koi发布了新的文献求助10
5秒前
7秒前
7秒前
罗小马完成签到 ,获得积分10
7秒前
8秒前
wyg117完成签到,获得积分10
9秒前
CipherSage应助Zard采纳,获得10
9秒前
10秒前
824发布了新的文献求助10
10秒前
Treasure完成签到,获得积分10
11秒前
xialuoke发布了新的文献求助10
12秒前
12秒前
12秒前
12秒前
852应助漂亮的冰菱采纳,获得10
12秒前
12秒前
Mo完成签到 ,获得积分10
13秒前
所所应助雨墨幻山采纳,获得10
14秒前
下不上文献的大越完成签到,获得积分10
14秒前
15秒前
15秒前
16秒前
17秒前
强健的冰棍完成签到,获得积分10
17秒前
hao发布了新的文献求助10
17秒前
任性静祝完成签到 ,获得积分10
17秒前
故意的幻然应助Let It Be采纳,获得20
20秒前
罗实完成签到 ,获得积分10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038619
求助须知:如何正确求助?哪些是违规求助? 3576294
关于积分的说明 11375058
捐赠科研通 3306084
什么是DOI,文献DOI怎么找? 1819374
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066